These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 28445879)

  • 21. Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica.
    Wilson R; Makuch M; Kienzler AK; Varley J; Taylor J; Woodhall M; Palace J; Leite MI; Waters P; Irani SR
    Brain; 2018 Apr; 141(4):1063-1074. PubMed ID: 29447335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures.
    Jarius S; Paul F; Franciotta D; Ruprecht K; Ringelstein M; Bergamaschi R; Rommer P; Kleiter I; Stich O; Reuss R; Rauer S; Zettl UK; Wandinger KP; Melms A; Aktas O; Kristoferitsch W; Wildemann B
    J Neurol Sci; 2011 Jul; 306(1-2):82-90. PubMed ID: 21550068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between serum levels of endothelin-1 and disease severity in patients with neuromyelitis optica spectrum disorders.
    Yi M; Liu MQ; Chou LS; Jiang SM; Zhang LJ; Huang CN; Wang N; Zhang QX; Yang L
    Immunobiology; 2020 May; 225(3):151959. PubMed ID: 32517881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased serum IL-27 and IL-35 levels are associated with disease severity in neuromyelitis optica spectrum disorders.
    Zhang DQ; Jia K; Wang R; Li T; Zhao N; Yang LN; Yang L
    J Neuroimmunol; 2016 Apr; 293():100-104. PubMed ID: 27049569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated serum interleukin-39 levels in patients with neuromyelitis optica spectrum disorders correlated with disease severity.
    Yang MG; Tian S; Zhang Q; Han J; Liu C; Zhou Y; Zhu J; Jin T
    Mult Scler Relat Disord; 2020 Nov; 46():102430. PubMed ID: 32853892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
    Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
    JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders.
    Dujmovic I; Mader S; Schanda K; Deisenhammer F; Stojsavljevic N; Kostic J; Berger T; Drulovic J; Reindl M
    J Neuroimmunol; 2011 May; 234(1-2):124-30. PubMed ID: 21316112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Circulating Follicular Helper T Cells and Serum CXCL13 With Neuromyelitis Optica Spectrum Disorders.
    Yang X; Peng J; Huang X; Liu P; Li J; Pan J; Wei Z; Liu J; Chen M; Liu H
    Front Immunol; 2021; 12():677190. PubMed ID: 34335576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis.
    Keller A; Leidinger P; Meese E; Haas J; Backes C; Rasche L; Behrens JR; Pfuhl C; Wakonig K; Gieß RM; Jarius S; Meder B; Bellmann-Strobl J; Paul F; Pache FC; Ruprecht K
    J Neuroinflammation; 2015 Oct; 12():196. PubMed ID: 26521232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuromyelitis optica spectrum disorder and multiple sclerosis: Differentiation by a multimodal approach.
    Ota M; Sato N; Okamoto T; Noda T; Araki M; Yamamura T; Kunugi H
    Mult Scler Relat Disord; 2015 Nov; 4(6):515-20. PubMed ID: 26590657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discrepancy in clinical and laboratory profiles of NMOSD patients between AQP4 antibody positive and negative: can NMOSD be diagnosed without AQP4 antibody?
    Chu F; Shi M; Liu C; Zhu J
    Clin Exp Immunol; 2023 Oct; 213(3):363-370. PubMed ID: 37161978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.
    Pröbstel AK; Rudolf G; Dornmair K; Collongues N; Chanson JB; Sanderson NS; Lindberg RL; Kappos L; de Seze J; Derfuss T
    J Neuroinflammation; 2015 Mar; 12():46. PubMed ID: 25889963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.
    Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M
    Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
    Yan Y; Li Y; Fu Y; Yang L; Su L; Shi K; Li M; Liu Q; Borazanci A; Liu Y; He Y; Bennett JL; Vollmer TL; Shi FD
    Sci China Life Sci; 2016 Dec; 59(12):1270-1281. PubMed ID: 26920678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder.
    Cho EB; Cho HJ; Seok JM; Min JH; Kang ES; Kim BJ
    Neurol Sci; 2018 Mar; 39(3):543-549. PubMed ID: 29349658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sudden hearing loss as the initial symptom in Japanese patients with multiple sclerosis and seropositive neuromyelitis optica spectrum disorders.
    Tanaka M; Tanaka K
    J Neuroimmunol; 2016 Sep; 298():16-8. PubMed ID: 27609270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.
    Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W
    J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-36 alpha levels are elevated in the serum and cerebrospinal fluid of patients with neuromyelitis optica spectrum disorder and correlate with disease activity.
    Song Y; Zhu M; Liu C; Zheng C; Zhou Y; Zhu J; Jin T
    Immunobiology; 2019 May; 224(3):397-401. PubMed ID: 30852049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.